Oncimmune Holdings PLCFRA Oncimmune Holdings Stock Report

Oncimmune Holdings Plc engages in diagnosing cancer. The company is headquartered in Nottingham, Nottinghamshire and currently employs 56 full-time employees. The company went IPO on 2016-05-18. The principal activity of the Company and its subsidiaries is that of autoantibodies profiling to the pharmaceutical and biotechnology industry, specifically in the areas of immune-oncology, autoimmune disease and infectious diseases, and the research, development and commercialization of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a range of solid tumor types. Its ImmunoINSIGHTS service business leverages its technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Its immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Its diagnostic products business is located at its laboratory facility in Nottingham, United Kingdom.